hypersplenism: Overactive functioning of the spleen, resulting in excessive destruction of blood cells.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
146 |
4. Check minimum number of eventsNone |
146 |
5. Include endpointsNone |
146 |
6. Filter based on genotype QC (FinnGen only) |
146 |
Control definitions (FinnGen only)
- Control exclude
- D3_BLOODOTHER
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- D73
- Name in latin
- Hypersplenismus
Similar endpoints
↥List of similar endpoints to
Hypersplenism
based on the number of shared cases.
Similar with more cases:
- Diseases of spleen
- Other diseases of blood and blood-forming organs, wide
- Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism
- Any operation in hilmo
- Any event in hilmo or specialist outpatient
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 1082 | 469 | 602 |
| Only index persons | 882 | 381 | 501 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.02 | 0.01 | 0.02 |
| Only index persons | 0.02 | 0.01 | 0.02 |
| Median age at first event (years) | |||
| Whole population | 58.66 | 59.57 | 57.67 |
| Only index persons | 56.73 | 57.62 | 56.06 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 146 | 63 | 83 |
| Unadjusted period prevalence (%) | 0.03 | 0.02 | 0.04 |
| Median age at first event (years) | 57.70 | 56.06 | 58.94 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 132
- Matched controls
- 1320
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
D73.1
ICD-10 Finland
Hypersplenism
4503599627370496.0
179.9
129
*
XW000
NOMESCO Finland
Bone marrow biopsy
47.8
39.1
47
15
D69.6
ICD-10 Finland
Thrombocytopenia, unspecified
54.2
28.4
33
8
R16.1
ICD-10 Finland
Splenomegaly, not elsewhere classified
160.2
25.6
26
*
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
9.2
22.0
51
84
D64.9
ICD-10 Finland
Anaemia, unspecified
10.3
20.1
42
57
JMA10
NOMESCO Finland
Transabdominal total splenectomy
+∞
17.0
16
*
JN1AE
NOMESCO Finland
Ultrasound examination of upper part of abdomen
9.3
16.2
35
49
A49.9
ICD-10 Finland
Bacterial infection, unspecified
8.3
15.4
36
57
JN4BD
NOMESCO Finland
Extensive body CT
8.0
15.1
36
59
D70.89
ICD-10 Finland
Neutropenic splenomegaly
+∞
14.9
14
*
K74.6
ICD-10 Finland
Other and unspecified cirrhosis of liver
32.1
13.3
17
6
117
Kela drug reimbursment
Leukaemia and other malignant diseases of the blood and bone marrow, and malignant diseases of the lymphatic tissue
16.4
13.3
21
15
C03DA01
ATC
spironolactone; oral
7.9
13.2
31
49
I85.9
ICD-10 Finland
Oesophageal varices without bleeding
55.9
13.1
15
*
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
4.2
13.1
67
260
WW500
NOMESCO Finland
Blood transfusion
11.7
11.5
21
21
C03CA01
ATC
furosemide; systemic
3.9
11.1
57
215
GD1AA
NOMESCO Finland
Thorax X-ray examination
3.4
10.5
78
390
R50.9
ICD-10 Finland
Fever, unspecified
4.7
10.4
38
104
M04AA01
ATC
allopurinol; systemic
5.1
9.9
33
81
TPH04
NOMESCO Finland
Cathetrisation of vein
4.0
9.9
46
157
ZX120
NOMESCO Finland
Intravenous
5.9
9.9
28
57
K70.3
ICD-10 Finland
Alcoholic cirrhosis of liver
26.1
9.1
12
5
JN3DE
NOMESCO Finland
Abdominal extensive ultrasoudn examination with blood flow measurements after transplantation
95.9
8.5
9
*
J01MA12
ATC
levofloxacin; systemic
3.5
8.5
45
169
D80.1
ICD-10 Finland
Nonfamilial hypogammaglobulinaemia
+∞
8.4
8
*
JMA11
NOMESCO Finland
Laparoscopic total splenectomy
+∞
8.4
8
*
JN3BD
NOMESCO Finland
Extensive abdominal CT
4.7
8.4
29
74
A46
ICD-10 Finland
Erysipelas
4.2
8.3
33
97
C83.80
ICD-10 Finland
B-cell lymphoma in marginal zone
35.7
8.2
10
*
GD1DD
NOMESCO Finland
High resolution CT examination of lungs
7.0
7.6
18
29
D47.1
ICD-10 Finland
Chronic myeloproliferative disease
84.6
7.5
8
*
120
Kela drug reimbursment
Hypogammaglobulinaemia
+∞
7.4
7
*
R59.0
ICD-10 Finland
Localized enlarged lymph nodes
9.6
7.3
14
16
WW200
NOMESCO Finland
Immunization
9.6
7.3
14
16
A05AA02
ATC
ursodeoxycholic acid; oral
21.4
7.2
10
5
L01XX05
ATC
hydroxycarbamide; oral
31.9
7.2
9
*
TNE25
NOMESCO Finland
Drill biopsy of bone marrow, pelvis
31.9
7.2
9
*
JN4AD
NOMESCO Finland
Body CT examination
5.2
7.2
22
49
J01MA02
ATC
ciprofloxacin; systemic
2.7
7.0
65
346
D50.9
ICD-10 Finland
Iron deficiency anaemia, unspecified
5.7
6.8
19
38
TPH07
NOMESCO Finland
Cathetrisation of artery
4.3
6.5
24
65
FM1EE
NOMESCO Finland
Extensive structural and functional ultrasound examination of heart
3.1
6.5
40
164
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
3.5
6.4
31
107
NEA10
NOMESCO Finland
Exploration of soft tissue of pelvis, percutaneous
+∞
6.3
6
*
K76.6
ICD-10 Finland
Portal hypertension
+∞
6.3
6
*
J06BA01
ATC
immunoglobulins, normal human, for extravascular adm.; systemic
+∞
6.3
6
*
TPH20
NOMESCO Finland
Insertion of central venous catheter through subclavian or brachiocephalic vein
8.3
6.3
13
17
KH1AE
NOMESCO Finland
Urinary tract ultrasound examination
5.9
6.1
16
30
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
57
88
9.99
38.60
4.4
2.4
0.2
0.2
g/l
1.77
52
81
34
25
17.43
37.81
6.6
2.0
47.7
34.4
umol/l
1.09
29
20
32
26
15.48
33.52
1.8
2.0
—
—
—
0
0
28
28
12.14
25.54
4.0
2.1
2.3
4.3
g/l
4.92
28
28
59
142
6.29
25.31
3.8
2.3
23.0
24.8
%
0.30
49
123
35
50
8.89
24.51
2.5
1.8
0.8
1.5
g/l
4.02
25
41
31
42
9.10
22.57
1.6
1.3
—
—
—
0
0
31
42
9.10
22.57
1.6
1.3
5.9
7.5
g/l
3.14
20
33
30
42
8.73
21.22
1.6
1.3
3.4
3.9
g/l
1.00
18
31
71
241
4.79
19.63
3.1
1.9
3.5
2.9
mg/l
1.04
60
210
20
18
12.72
19.30
1.5
1.3
—
—
—
0
0
126
674
7.35
19.29
22.3
8.8
4.4
4.2
e9/l
0.09
117
581
27
38
8.49
18.92
1.7
1.3
2.8
2.9
g/l
0.08
18
32
50
135
5.11
18.20
9.1
2.8
10.9
4.9
umol/l
2.29
44
116
18
16
12.69
17.43
1.2
1.3
278.5
195.4
u/ml
—
8
9
18
18
11.27
16.14
1.2
1.2
—
—
—
0
0
15
12
13.82
15.38
1.1
1.2
—
—
—
0
0
54
180
4.17
14.65
2.1
1.7
1242.2
1231.1
nmol/l
0.03
44
148
102
533
4.03
14.11
13.7
6.9
1.2
1.2
mmol/l
1.47
88
461
52
174
4.09
13.96
3.5
1.9
—
—
—
0
0
17
6
31.75
13.29
3.6
2.2
1508.5
793.7
u/ml
—
17
6
31
72
5.20
13.16
3.4
1.6
—
—
—
0
0
70
311
3.40
11.95
5.0
2.4
347.2
4980.1
umol/l
1.30
64
270
19
30
7.13
11.87
3.4
1.8
—
—
—
0
0
19
30
7.13
11.87
2.0
1.1
—
—
—
0
0
16
8
22.22
11.41
2.4
2.1
—
—
—
0
0
38
117
4.04
11.23
2.5
1.8
—
—
—
0
0
12
11
11.80
11.20
4.2
1.6
264.0
644.0
e6/l
—
6
6
38
121
3.89
10.67
2.6
1.8
—
—
—
0
0
74
360
3.14
10.55
5.3
2.8
56.6
54.3
u/l
0.11
68
337
16
25
7.06
10.03
3.1
1.6
—
—
—
0
0
19
36
5.92
9.93
2.3
3.2
—
—
—
0
0
17
29
6.50
9.84
3.9
1.8
—
—
—
0
0
18
33
6.08
9.72
2.2
1.3
1.1
1.1
g/l
0.17
18
33
11
11
10.73
9.66
3.6
1.4
34.0
34.2
pg
0.05
11
11
14
20
7.64
9.46
3.7
1.7
—
—
—
0
0
58
266
2.96
8.88
6.2
2.2
—
—
—
0
0
22
54
4.62
8.61
7.0
3.9
23.9
24.6
mmol/l
0.42
22
46
92
545
2.86
8.60
10.6
4.2
—
—
—
0
0
13
19
7.41
8.59
6.0
3.8
60.4
60.3
%
0.00
13
19
13
19
7.41
8.59
1.7
1.5
—
—
—
0
0
12
17
7.60
8.12
1.8
1.4
—
—
—
0
0
15
28
5.86
7.91
4.5
2.0
180.5
200.1
%
0.25
15
28
17
36
5.21
7.86
2.6
3.2
—
—
—
0
0
76
423
2.66
7.80
2.8
1.8
100.7
95.3
pmol/l
0.31
44
215
32
111
3.41
7.77
6.2
3.5
1.9
1.9
mmol/l
0.01
27
85
12
9
14.38
7.53
1.1
1.0
—
—
—
0
0
14
26
5.85
7.41
2.0
1.7
—
—
—
0
0
12
19
6.79
7.36
5.1
2.9
4.2
4.8
e9/l
0.18
12
19
16
35
5.01
7.12
1.4
1.3
—
—
—
0
0
23
69
3.77
6.89
6.1
3.5
1.3
1.5
mmol/l
0.09
14
50
73
417
2.50
6.86
5.1
3.0
—
—
—
0
0
10
6
17.74
6.85
1.1
1.0
—
—
—
0
0
13
25
5.61
6.62
1.2
1.3
—
—
—
0
0
10
7
15.20
6.49
1.4
1.1
3.1
4.9
mg/l
—
10
7
50
245
2.58
6.43
3.0
1.6
1.6
1.0
mg/l
0.65
40
191
10
8
13.30
6.18
1.7
1.3
—
—
—
0
0
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
14
33
4.59
5.70
5.7
2.3
0.4
0.3
u/ml
—
8
19
9
7
13.59
5.66
2.2
2.0
24.0
10.9
u/l
—
9
7
11
21
5.58
5.62
2.2
1.8
—
—
—
0
0
11
21
5.58
5.62
2.2
1.8
—
—
—
0
0
59
333
2.30
5.42
4.8
2.9
0.2
0.4
e6/l
0.89
47
247
12
26
4.94
5.36
1.7
1.5
—
—
—
0
0
12
26
4.94
5.36
1.7
1.5
—
—
—
0
0
8
6
14.00
5.14
1.1
1.3
—
—
—
0
0
8
6
14.00
5.14
2.5
1.3
—
—
—
0
0
8
6
14.00
5.14
2.5
1.3
—
—
—
0
0
20
68
3.25
4.94
1.3
1.4
—
—
—
0
0
9
11
8.63
4.63
2.0
1.6
—
—
—
0
0
7
5
14.60
4.62
1.1
3.0
—
—
—
0
0
7
5
14.60
4.62
1.1
3.0
—
—
—
0
0
8
8
10.49
4.58
2.7
1.9
—
—
—
0
0
9
12
7.91
4.42
1.4
1.2
—
—
—
0
0
31
143
2.48
4.38
9.6
6.0
103.1
103.9
mmol/l
0.37
31
138
7
6
12.16
4.32
2.7
1.3
—
—
—
0
0
7
6
12.16
4.32
2.7
1.3
—
—
—
0
0
31
145
2.44
4.25
3.4
2.0
1.6
1.5
%
0.30
25
129
11
27
4.32
4.24
4.2
1.4
—
—
—
0
0
9
13
7.29
4.23
4.3
1.8
—
—
—
0
0
9
13
7.29
4.23
4.3
1.8
—
—
—
0
0
9
13
7.29
4.23
4.3
1.8
—
—
—
0
0
29
134
2.45
4.08
7.0
9.9
1.0
1.4
mmol/l
0.21
24
107
7
7
10.42
4.05
5.3
2.4
—
—
—
0
0
7
7
10.42
4.05
5.3
2.4
—
—
—
0
0
7
7
10.42
4.05
5.3
2.4
—
—
—
0
0
7
7
10.42
4.05
5.3
2.4
—
—
—
0
0
9
14
6.77
4.05
1.1
1.8
—
—
—
0
0
17
60
3.07
3.94
6.5
5.4
25.1
24.6
mmol/l
0.17
17
60
16
55
3.14
3.87
2.7
1.5
—
—
—
0
0
17
61
3.02
3.84
6.6
7.8
23.8
24.7
mmol/l
0.39
17
56
10
25
4.22
3.76
1.2
1.4
—
—
—
0
0
14
45
3.34
3.76
4.9
2.3
—
—
—
0
0
9
16
5.92
3.72
4.9
1.7
—
—
—
0
0
44
254
2.05
3.60
2.2
1.4
17.5
22.2
nmol/l
1.35
44
214
9
17
5.56
3.57
4.9
1.6
—
—
—
0
0
8
13
6.44
3.55
1.1
1.2
—
—
—
0
0
35
186
2.16
3.55
3.5
2.8
2.1
1.4
e6/l
0.33
16
105
6
6
10.35
3.53
2.2
1.8
—
—
—
0
0
6
6
10.35
3.53
5.8
2.3
—
—
—
0
0
6
6
10.35
3.53
5.8
2.3
—
—
—
0
0
6
6
10.35
3.53
2.2
1.8
—
—
—
0
0
6
6
10.35
3.53
5.8
2.3
—
—
—
0
0
6
6
10.35
3.53
6.5
1.3
—
—
—
0
0
43
248
2.04
3.52
1.3
1.3
1.0
0.9
u/ml
0.13
12
78
17
66
2.78
3.35
4.2
2.5
1.9
1.4
%
0.37
17
66
6
8
7.76
3.08
2.3
1.6
—
—
—
0
0
12
40
3.18
3.05
2.6
1.5
—
—
—
0
0
8
17
4.91
2.96
5.0
1.4
—
—
—
0
0
8
17
4.91
2.96
5.0
1.4
—
—
—
0
0
22
104
2.31
2.93
5.3
3.5
—
—
—
0
0
6
9
6.89
2.89
2.2
1.8
—
—
—
0
0
8
18
4.64
2.84
5.0
1.4
—
—
—
0
0
8
18
4.64
2.84
5.0
1.4
—
—
—
0
0
8
18
4.64
2.84
5.0
1.4
—
—
—
0
0
8
18
4.64
2.84
5.0
1.4
—
—
—
0
0
35
203
1.95
2.78
3.3
2.5
0.7
0.9
e6/l
0.41
17
121
63
443
1.74
2.69
6.1
3.7
25.9
38.5
ng/l
0.73
51
300
104
845
1.80
2.63
4.4
3.8
14.5
14.9
pmol/l
0.97
96
773
9
25
3.77
2.62
1.6
1.1
—
—
—
0
0
12
45
2.82
2.52
3.2
1.9
—
—
—
0
0
19
91
2.25
2.46
3.2
2.4
17.3
9.4
ug/l
0.35
13
83
9
27
3.48
2.44
2.4
1.4
—
—
—
0
0
5
9
5.71
2.23
1.2
1.3
—
—
—
0
0
50
346
1.68
2.18
4.9
4.2
35.9
13.7
mg/mmol
0.67
36
234
31
189
1.81
2.10
1.3
1.2
46.1
5.6
u/ml
—
8
78
5
11
4.66
1.95
1.0
1.2
—
—
—
0
0
5
11
4.66
1.95
1.0
1.2
—
—
—
0
0
5
11
4.66
1.95
1.0
1.2
—
—
—
0
0
5
11
4.66
1.95
1.0
1.2
—
—
—
0
0
5
11
4.66
1.95
1.0
1.2
—
—
—
0
0
132
1197
2.07
1.85
49.0
13.6
21.6
24.2
mg/l
0.58
126
940
32
205
1.72
1.83
1.5
1.2
150.4
35.1
iu/ml
0.45
11
66
73
574
1.54
1.81
5.1
3.3
0.0
0.0
estimate
0.00
21
122
32
207
1.70
1.77
5.1
3.6
706.5
265.7
ng/l
0.28
27
161
5
13
3.94
1.73
1.2
1.1
—
—
—
0
0
72
579
1.48
1.53
5.1
3.3
0.0
0.0
estimate
0.00
20
113
6
21
2.93
1.52
2.7
1.1
—
—
—
0
0
45
329
1.53
1.51
3.3
2.0
96.5
253.5
u/l
1.97
45
312
44
321
1.53
1.49
6.5
3.3
0.0
0.0
estimate
0.00
18
117
71
574
1.46
1.45
6.2
4.5
0.0
0.0
estimate
0.00
20
122
7
29
2.48
1.41
1.4
1.4
—
—
—
0
0
123
1115
1.65
1.40
39.2
12.6
80.2
82.7
ml/min/173m2
0.46
104
917
13
69
1.97
1.33
1.2
1.2
28.8
139.6
iu/ml
—
5
23
16
94
1.79
1.23
2.9
2.7
45.0
67.2
ml/min/173m2
—
8
39
5
113
0.42
1.18
1.4
1.6
—
—
—
0
0
8
39
2.11
1.17
1.5
1.4
—
—
—
0
0
9
160
0.53
1.06
1.7
1.5
—
—
—
0
0
109
1172
0.72
0.88
5.2
4.3
1.2
1.4
mmol/l
8.70
102
1090
106
1141
0.74
0.82
5.6
3.9
1.4
1.3
mmol/l
0.96
98
1056
6
33
1.85
0.80
1.2
1.1
—
—
—
0
0
114
1058
1.35
0.76
5.6
4.4
2.2
1.9
mu/l
1.25
106
974
113
1199
0.75
0.71
5.5
4.8
2.3
2.8
mmol/l
5.80
107
1113
111
1178
0.76
0.67
5.3
4.3
4.1
4.6
mmol/l
7.25
105
1104
116
1088
1.32
0.65
47.7
14.3
37.7
40.7
%
2.74
85
819
54
464
1.26
0.63
5.8
3.4
—
—
—
0
0
6
35
1.74
0.58
1.8
1.2
—
—
—
0
0
6
35
1.74
0.58
1.8
1.2
—
—
—
0
0
8
60
1.35
0.41
1.8
1.3
—
—
—
0
0
113
1092
1.15
0.26
8.5
5.6
40.0
40.0
mmol/mol
0.00
102
1037
0
12
0.00
0.21
0.0
1.4
—
—
—
0
0
23
203
1.16
0.20
2.0
1.5
—
—
—
0
0
79
755
1.10
0.19
4.1
3.1
—
—
—
0
0
12
135
0.88
0.10
14.2
7.9
—
—
—
0
0
116
1141
1.08
0.10
6.2
4.4
6.4
6.0
mmol/l
1.55
110
1053
34
359
0.93
0.09
4.0
4.3
21.6
20.2
%
0.16
13
176
5
60
0.83
0.08
1.0
1.0
—
—
—
0
0
13
139
0.93
0.03
1.8
1.9
—
—
—
0
0
13
129
1.01
0.00
1.4
1.8
—
—
—
0
0
27
268
1.01
0.00
3.0
2.9
0.7
0.7
ug/l
0.06
19
175
11
115
0.95
0.00
2.3
2.2
11.2
13.3
nmol/l
0.48
11
108
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
2.4
—
43.6
—
0
7
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
0.00
0.0
1.2
—
—
—
0
0
0
9
0.00
0.00
0.0
1.0
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint D3_HYPERSPLENISM and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| D3_HYPERSPLENISM | 6.062 [3.72, 9.87] | < 0.001 |
| Birth year | 0.995 [0.99, 1.0] | 0.274 |
During the follow-up period (1.1.1998 — 31.12.2019), 136 out of 361 females with D3_HYPERSPLENISM died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| D3_HYPERSPLENISM | 4.648 [3.31, 6.52] | < 0.001 |
| Birth year | 0.986 [0.98, 1.0] | 0.004 |
During the follow-up period (1.1.1998 — 31.12.2019), 174 out of 469 males with D3_HYPERSPLENISM died.
Mortality risk
Mortality risk for people of age
years, who have D3_HYPERSPLENISM.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.658% | 0.829% |
| 5 | 3.469% | 5.303% |
| 10 | 8.399% | 13.102% |
| 15 | 16.608% | 22.798% |
| 20 | 27.309% | 36.245% |
Relationships between endpoints
↥Index endpoint: D3_HYPERSPLENISM – Hypersplenism
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data